Holding(s) in Company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

GW Pharmaceuticals plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation:

 Great Point Partners LLC

4. Full name of shareholder(s) (if different from 3.):

Biomedical Value Fund, L.P.

Biomedical Institutional Value Fund, L.P.

Biomedical Offshore Value Fund Ltd.

5. Date of the transaction and date on which the threshold is crossed or reached:

 January 7, 2011

6. Date on which issuer notified:

 February 17, 2011

7. Threshold(s) that is/are crossed or reached:

 Less than 5%

8. Notified details:

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary shares

6,602,000

 6,602,000

 5,852,000

5,852,000

 -

 4.45%

-

 GB0030544687

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate

Exercise/ConversionPeriod

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 5,852,000

4.45%

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 Biomedical Value Fund, L.P

165 Mason Street

3rd Floor, Greenwich

CT 06830

Biomedical Institutional Value Fund, L.P

165 Mason Street

3rd Floor, Greenwich

CT 06830

Biomedical Offshore Value Fund, Ltd

165 Mason Street

3rd Floor, Greenwich

CT 06830

Proxy Voting:

10. Name of the proxy holder:

 -

11. Number of voting rights proxy holder will cease to hold:

 -

12. Date on which proxy holder will cease to hold voting rights:

 -

13. Additional information:

14. Contact name:

Ron Panzier

Chief Financial Officer

Great Point Partners LLC

15. Contact telephone number:

 001-203-971-3300

16. Contact number at the Company:

Adam George

Company Secretary

+ 44 (0) 1980 557 000